The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation: – The J-ROCKET AF Study –
Open accessAbstract
BACKGROUND: The global ROCKET AF study evaluated once-daily rivaroxaban vs. warfarin for stroke and systemic embolism prevention in patients with atrial fibrillation (AF). A separate trial, J-ROCKET AF, compared the safety of a Japan-specific rivaroxaban dose with warfarin administered according to Japanese guidelines in Japanese patients with AF. METHODS AND RESULTS: J-ROCKET AF was a prospective, randomized, double-blind, phase III trial. Patients (n=1,280) with non-valvular AF at increased risk for stroke were randomized to receive 15 mg once-daily rivaroxaban or warfarin dose-adjusted according to Japanese guidelines. The primary objective was to determine non-inferiority of rivaroxaban against warfarin for the principal safety outcome of major and non-major clinically relevant bleeding, in the on-treatment safety population. The primary efficacy endpoint was the composite of stroke and systemic embolism. Non-inferiority of rivaroxaban to warfarin was confirmed; the rate of the principal safety outcome was 18.04% per year in rivaroxaban-treated patients and 16.42% per year in warfarin-treated patients (hazard ratio [HR] 1.11; 95% confidence interval 0.87-1.42; P<0.001 [non-inferiority]). Intracranial hemorrhage rates were 0.8% with rivaroxaban and 1.6% with warfarin. There was a strong trend for a reduction in the rate of stroke/systemic embolism with rivaroxaban vs. warfarin (HR, 0.49; P=0.050). CONCLUSIONS: J-ROCKET AF demonstrated the safety of a Japan-specific rivaroxaban dose and supports bridging the global ROCKET AF results into Japanese clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Wallentin, L., Yusuf, S., Ezekowitz, M. D., Alings, M., Flather, M., Franzosi, M. G., Pais, P., Dans, A., Eikelboom, J., Oldgren, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61194-4 · Cited by 1,013
Fox, K. A. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., Paolini, J. F., Hankey, G. J., Mahaffey, K. W., Patel, M. R., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr342 · Cited by 608
Oates, J. A., Wood, A. J. J., & Hirsh, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106273242606 · Cited by 563
Yasaka, M., Minematsu, K., & Yamaguchi, T. (2001) · Internal Medicine · doi:10.2169/internalmedicine.40.1183 · Cited by 221
Atarashi, H., Inoue, H., Okumura, K., Yamashita, T., Kumagai, N., Origasa, H., & The J-RHYTHM Registry Investigators (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1119 · Cited by 199
Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008)
JCS Joint Working Group (2010) · Circulation Journal · doi:10.1253/circj.cj-88-0001 · Cited by 137
Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008) : Digest Version
Ogawa, S., Aizawa, Y., Atarashi, H., Inoue, H., Kamakura, S., Koretsune, Y., Kumagai, K., Mitamura, H., Okumura, K., Sugi, K., et al. (2010) · Japanese Circulation Journal-english Edition · Cited by 130
Self-citation
Cited by
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Antithrombotic Therapy for Atrial Fibrillation
Lip, G. Y. H., Banerjee, A., Boriani, G., Chiang, C. E., Fargo, R., Freedman, B., Lane, D. A., Ruff, C. T., Turakhia, M., Werring, D., et al. (2018) · Chest · doi:10.1016/j.chest.2018.07.040 · Cited by 939
Metadata
- Authors
- Hori, M., Matsumoto, M., Tanahashi, N., Momomura, S.-I., Uchiyama, S., Goto, S., Izumi, T., Koretsune, Y., Kajikawa, M., Kato, M., Ueda, H., Iwamoto, K., Tajiri, M., & on behalf of the J-ROCKET AF study investigators
- Venue
- Circulation Journal
- Publisher
- Japanese Circulation Society
- Published
- 2012
- Volume
- 76
- Issue
- 9
- Pages
- 2104-2111
- ISSN
- 1346-9843 (ISSN-L)
- 1347-4820
- OpenAlex
- W2320128544
- Cited by
- 641
- References
- 13
- FWCI
- 32.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation: – The J-ROCKET AF Study –. https://app.cochat.ai/papers/10.1253/circj.cj-12-0454
- The paper
- Hori, M., Matsumoto, M., Tanahashi, N., Momomura, S.-I., Uchiyama, S., Goto, S., Izumi, T., Koretsune, Y., Kajikawa, M., Kato, M., Ueda, H., Iwamoto, K., Tajiri, M., & on behalf of the J-ROCKET AF study investigators. (2012). Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation: – The J-ROCKET AF Study –. Circulation Journal. https://doi.org/10.1253/circj.cj-12-0454
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
